What is the price-to-earnings ratio of Mustang Bio?
The price-earnings ratio of Mustang Bio is currently 0.
Mustang Bio P/S 2024
Mustang Bio P/S
0
Ticker
MBIO
ISIN
US62818Q1040
WKN
A2DWVA
As of Sep 19, 2024, Mustang Bio's P/S ratio stood at 0, a 0% change from the 0 P/S ratio recorded in the previous year.
The Mustang Bio P/S history
Mustang Bio Aktienanalyse
What does Mustang Bio do?
Mustang Bio Inc. is a rising biotechnology company that was founded in 2015. Based in Massachusetts, the company specializes in the development of novel genetically modified CAR-T cell therapies for various types of cancer. Mustang Bio's business model is focused on developing and ultimately commercializing groundbreaking, differentiated technologies for the treatment of cancer. The company utilizes its expertise in genetic sequencing research and development, as well as extensive knowledge in the clinical testing of drugs. Mustang Bio has three main divisions: therapeutics, partnerships, and platform technology. The therapeutics division serves as the company's development and marketing arm. Here, innovative CAR-T cell therapies for the treatment of various types of cancer, including hematological and solid tumors, are researched and developed. Mustang Bio has several drug candidates in different phases of clinical development, including MB-106 and MB-107, targeting the treatment of acute myeloid leukemia (AML) and B-cell lymphomas. The partnerships division collaborates with other companies and industry stakeholders to jointly develop new technologies and share research findings. Mustang Bio has already formed several partnerships with other companies, including the Nationwide Children's Hospital and the City of Hope. These partnerships have contributed to advancing research and development in oncology and sharing the costs and risks associated with developing new therapeutics. The platform technology division serves as the technological arm of the company. Here, new technologies and platforms for the discovery and development of innovative therapeutics are developed and improved. This division aims to develop more effective and safer therapies while reducing development time and costs. Mustang Bio takes pride in developing some of the most innovative and advanced technologies for the treatment of cancer. By utilizing genetic sequences and gene editing tools such as CRISPR/Cas9, the company has developed unique CAR-T cell therapies that can specifically target and eliminate tumor cells. The company has already achieved significant milestones, such as receiving Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for MB-107 in the treatment of X-linked severe combined immunodeficiency (XSCID). Additionally, Mustang Bio has signed an exclusive license agreement with St. Jude Children's Research Hospital to develop a new method for oncofusion targeting the treatment of refractory leukemias. Mustang Bio also has a strong leadership team and board of directors consisting of renowned scientists, doctors, and entrepreneurs. The company has also received strong support from its investors and shareholders who believe in the company's potential to change the cancer treatment paradigm. In summary, Mustang Bio is a company dedicated to developing innovative therapeutics for the treatment of cancer. The company leverages its expertise in genome editing research and development, as well as its experience in clinical drug testing, to develop novel, differentiated, and effective CAR-T cell therapies for various types of cancer. Mustang Bio has also built strong partnerships with other companies and industry stakeholders to jointly develop new technologies and therapeutics. Mustang Bio ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Mustang Bio's P/S Ratio
Mustang Bio's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Mustang Bio's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Mustang Bio's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Mustang Bio’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Mustang Bio stock
How has the price-earnings ratio of Mustang Bio changed compared to last year?
The price-to-earnings ratio of Mustang Bio has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Mustang Bio high compared to other companies?
Yes, the price-to-earnings ratio of Mustang Bio is high compared to other companies.
How does an increase in the price-earnings ratio of Mustang Bio affect the company?
An increase in the price-earnings ratio of Mustang Bio would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Mustang Bio affect the company?
A decrease in the price-earnings ratio of Mustang Bio would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Mustang Bio?
Some factors that influence the price-earnings ratio of Mustang Bio are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Mustang Bio pay?
Over the past 12 months, Mustang Bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mustang Bio is expected to pay a dividend of 0 USD.
What is the dividend yield of Mustang Bio?
The current dividend yield of Mustang Bio is .
When does Mustang Bio pay dividends?
Mustang Bio pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Mustang Bio?
Mustang Bio paid dividends every year for the past 0 years.
What is the dividend of Mustang Bio?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Mustang Bio located?
Mustang Bio is assigned to the 'Health' sector.
Wann musste ich die Aktien von Mustang Bio kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Mustang Bio from 9/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/19/2024.
When did Mustang Bio pay the last dividend?
The last dividend was paid out on 9/19/2024.
What was the dividend of Mustang Bio in the year 2023?
In the year 2023, Mustang Bio distributed 0 USD as dividends.
In which currency does Mustang Bio pay out the dividend?
The dividends of Mustang Bio are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Mustang Bio stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Mustang Bio
Our stock analysis for Mustang Bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mustang Bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
